Visterra advances universal flu antibody to cusp of Phase I

Massachusetts-based biotech Visterra is preparing to move its universal influenza therapy into the clinic. Visterra is talking up the engineered antibody as way to both prevent and treat seasonal and pandemic flu infections. News

Suggested Articles

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.